SEC Form 4 · accession 0001562180-18-004219

G1 Therapeutics, Inc. · GTHX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Ch. Medical Officer & SVP R&D

Period of report

Oct 15, 2018

Accepted (ET)

Oct 15, 2018 · 5:57 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001560241

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Oct 15, 2018	M	3,776	$4.17	A	12,176	D
Common Stock^F2	Oct 15, 2018	S	943	$40.8041	D	11,233	D
Common Stock^F3	Oct 15, 2018	S	2,833	$42.0115	D	8,400	D
Common Stock	Oct 15, 2018	M	6,300	$0.39	A	14,700	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Options (Right to Buy)^F4	$4.17	Oct 15, 2018	M	3,776	D	—	May 10, 2026	Common Stock	3,776	73,071	D
Stock Option (Right to Buy)^F5	$0.39	Oct 15, 2018	M	6,300	D	—	Jul 11, 2024	Common Stock	6,300	97,444	D

F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2The price represents the weighted average price with a low of $40.60 and a high of $40.99. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 and 3 to this Form 4.
F3The price represents the weighted average price with a low of $41.95 and a high of $42.29.
F4The shares underlying this option vested as to 25% of the shares on May 10, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F5All shares underlying this option have vested.